On Friday, Pacira BioSciences Inc (NASDAQ: PCRX) was -1.23% drop from the session before settling in for the closing price of $26.07. A 52-week range for PCRX has been $11.16 – $31.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 11.26%. When this article was written, the company’s average yearly earnings per share was at -11.38%. With a float of $44.27 million, this company’s outstanding shares have now reached $46.28 million.
The extent of productivity of a business whose workforce counts for 790 workers is very important to gauge. In terms of profitability, gross margin is 73.54%, operating margin of -11.65%, and the pretax margin is -9.68%.
Pacira BioSciences Inc (PCRX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pacira BioSciences Inc stocks. The insider ownership of Pacira BioSciences Inc is 4.39%, while institutional ownership is 111.29%. The most recent insider transaction that took place on Mar 06 ’25, was worth 11,625. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Medical Officer sold 879 for $18.40, making the entire transaction worth $16,174. This insider now owns 93,444 shares in total.
Pacira BioSciences Inc (PCRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -11.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.67% during the next five years compared to -51.99% drop over the previous five years of trading.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
You can see what Pacira BioSciences Inc (PCRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.70. Likewise, its price to free cash flow for the trailing twelve months is 7.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.29, a number that is poised to hit 0.69 in the next quarter and is forecasted to reach 3.43 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
The latest stats from [Pacira BioSciences Inc, PCRX] show that its last 5-days average volume of 0.76 million was inferior to 0.91 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 75.32%. Additionally, its Average True Range was 1.18.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 80.04%, which indicates a significant increase from 70.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.89% in the past 14 days, which was lower than the 50.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.07, while its 200-day Moving Average is $20.35. Now, the first resistance to watch is $26.17. This is followed by the second major resistance level at $26.60. The third major resistance level sits at $26.96. If the price goes on to break the first support level at $25.39, it is likely to go to the next support level at $25.03. The third support level lies at $24.60 if the price breaches the second support level.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
There are 46,291K outstanding shares of the company, which has a market capitalization of 1.19 billion. As of now, sales total 700,970 K while income totals -99,560 K. Its latest quarter income was 168,920 K while its last quarter net income were 4,810 K.
